Suzhou Ribo Life Science, Ribocure Pharmaceuticals, RBD3133, Obesity, Overweight, INHBE, siRNA Therapeutics, RNA Interference, Gene Silencing, Cardiometabolic Disease, Phase I Clinical Trial

Suzhou, China, and Mölndal, Sweden, October 7, 2026 Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals...